Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Researchers studied the medical records of more than 1 million children and young adults aged 2 to 24 who were taking or had taken stimulants such as Ritalin or Adderall and found no sign of increased risk of heart problems. “We don’t see any evidence of increased risk,” said Dr. William Cooper of Vanderbilt University, whose study was published in the New England Journal of Medicine. The study in children is the first of three commissioned by the Food and Drug Administration to understand the potential heart risks of the drugs after U.S. and Canadian regulators received a number of reports in 2006 of heart attacks, strokes and sudden cardiac arrest in children taking the medications. The reports prompted several FDA advisory committee hearings on heart problems, and Health Canada temporarily suspended marketing of ADHD drugs. The concerns also prompted the American Heart Association to issue guidelines suggesting that children who were just starting to take the drugs should be tested for potential underlying heart problems. “There was a lot of concern and confusion among families and providers about what the best approach would be to treating kids who had ADHD and who might benefit from these medicines,” Cooper said by phone. ADHD is one of the most common child mental disorders, affecting around 3 to 5 percent of children globally. Children with ADHD are excessively restless, impulsive and easily distracted, and often have trouble at home and in school. There is no cure, but the symptoms can be kept in check by a combination of behavioral therapy and medication. In the United States, some 2.7 million children have prescriptions for ADHD drugs including Novartis’ Ritalin or methylphenidate and Focalin; Johnson & Johnson’s Concerta, Shire’s Adderall and Vyvanse and Eli Lilly’s Strattera. For the study, Cooper’s team used prescription data from four large, geographically and demographically diverse health plans on 1,200,438 children and youth, including both current and past users of the drugs. They checked health records for evidence of heart problems, including heart attacks, strokes and sudden cardiac deaths, in children who were currently taking the drugs or who had taken them. The team found no increased risk of heart problems for either current or past users of the drugs. Yet because there were so few cases of serious heart problems — just 81 — the study may not have been large enough to detect it. But even if there were a risk of heart problems, it is extremely slight, Cooper said. In a guidance document issued on Tuesday, the FDA said it continues to recommend that the drugs not be used in patients with serious heart problems. It added that patients should be monitored for changes in heart rate or blood pressure. Jefferies analyst Peter Welford said the findings will likely reassure investors in Shire, maker of Adderall and Vyvanse. But because there were so few heart problems, the study was underpowered and cannot conclusively dispel concerns about cardiovascular risks. Shire’s shares were flat on Tuesday, outperforming a sharply lower market.
[EX A]: ADHD drugs do not increase heart problems in kids.

[EX Q]: "The article states that the costs are “generally … close to $45,000.” The news story notes in a sentence that hip replacement has a success rate of more than 90%, and defines “success” as “relatively pain-free mobility.” The article also clearly states why this new device was developed — to provide longer lifetime use prior to device failure. It quantifies this benefit vaguely, saying the device is ""much more durable"" and lasts ""much longer."" The news story focuses on one main harm—squeaking in hip implants made of ceramic—and provides estimates of its prevalence. A spokesperson for the hip maker points out that hip replacement has other potential risks as well, including infection, dislocation, and leg-length discrepancy. The news story makes it fairly clear that the research it is citing is from cohort studies. The first mention of the prevalence of squeaking in ceramic hip implants appears to cite the highest known estimate—7% of ceramic implants in one study of 143 patients. Only later do readers discover that other studies suggest the prevalence of the problem may be much smaller, from 3% (in a study of 1500 people) to less than 1%. This is not disease mongering, but it could cause some people to fear ceramic hip implants more than may be justified. In addition, the Times article says no squeaking occurred in patients with metal and plastic implants. But a recent 2007 review in the Journal of Bone & Joint Surgery (JBJS) reported that squeaking in similar implants made out of metal and plastic occurred in 4% of patients. (JBJS 2007;89:1874-85) If the JBJS review is accurate, the news story would be misleading. Unfortunately, the JBJS failed to support its own contention with a complete reference. The story cites 4 patients, 4 surgeons, a spokesperson for implant maker Stryker, and a lawyer representing aggrieved patients. All in all, they provide a balance of viewpoints. The story mentions a conflict of interest for one surgeon. It appears that 2 of the patients are clients of the lawyer. The story points out that the alternatives to a ceramic total hip replacement include hip replacements with implants made from metal and plastic. It doesn’t mention whether there are nonsurgical alternatives to hip replacement, but this is beyond the scope of the story. The story does not explicitly state that ceramic hip replacements are approved by the FDA, but with “tens of thousands” implanted, it’s clear that surgeons’ adoption of the devices is widespread. The FDA’s warning to implant maker Stryker about squeaking suggests the devices may not be perfect, but are approved. The story notes that Stryker introduced ceramic hip implants into the U.S. in 2003. The story cites several sources and does not appear to rely solely or largely on a news release."
[EX A]: That Must Be Bob. I Hear His New Hip Squeaking.

[EX Q]: "The story does not mention the costs of zinc products. The story does a good job of describing how many studies showed no effect of the zinc products. In the one study showing a benefit of zinc nasal gel, the story provides quantification of benefits in natural frequencies (days of duration of the cold) rather than in terms of relative reduction. The story discusses unpleasant taste, upset stomatch, stinging sensation and, potentially, loss of smell as harms or side effects of zinc products. The story does a great job of describing the design of the current study, which is a special kind of literature review. The story does not exaggerate the seriousness or prevalence of colds. In fact the writer could have emphasized that colds are expensive, resulting in lost productivity and sick days due to illness in workers and their children. The story quotes an independent expert as well as the lead author on the current study and the representative of the manufacturer. The story mentions over-the-counter antihistamines, decongestants, and pain releivers as alternatives, appropriately pointing out that there is no ""cure"" for the common cold. The story clearly states that zinc products are available over the counter in drugstores. The story clearly states that zinc products are not a new idea. Because the story quotes multiple experts, the reader can assume that the story does not rely on a press release as the sole source of information."
[EX A]:
An element of mystery in zinc cold treatments